 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...151152153154155156157158159160161...235236» |
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer. (Pubmed Central) - Jun 9, 2020
Chemotherapy regimens included gemcitabine (n=17), gemcitabine/nab-paclitaxel (n=8), or 5-FU/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) (n=11)...A short course of neoadjuvant chemotherapy without chemoradiation may improve patient selection prior to surgical resection for pancreas cancer. Further, local disease progression did not limit surgical resection in this small series.
- | leucovorin calcium / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer (clinicaltrials.gov) - Jun 9, 2020
P=N/A, N=48, Active, not recruiting, Sponsor: Vastra Gotaland Region
Further, local disease progression did not limit surgical resection in this small series. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- || Aphexda (motixafortide) / BioLineRx, Ayrmid
Enrollment closed, Metastases: COMBAT: Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Jun 9, 2020
P2a, N=80, Active, not recruiting, Sponsor: BioLineRx, Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Active, not recruiting
- || Jemperli (dostarlimab-gxly) / GSK
Enrollment change, Combination therapy, Metastases: CITRINO: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 9, 2020
P1, N=55, Recruiting, Sponsor: Tesaro, Inc.
Recruiting --> Active, not recruiting N=200 --> 55
- | New trial, Metastases: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 8, 2020
P, N=250, Recruiting, Sponsor: Oslo University Hospital
- | BOLD-100 / Bold Therap
New P1 trial, Combination therapy, Metastases: BOLD-100-001: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours (clinicaltrials.gov) - Jun 8, 2020
P1b, N=80, Not yet recruiting, Sponsor: Bold Therapeutics, Inc.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. (Pubmed Central) - Jun 8, 2020
Baseline SMI has an impact on prognosis in patients who undergoing second-line chemotherapy for pancreatic cancer. Skeletal muscle mass may warrant consideration as a predictive factor with which to identify candidates for second-line chemotherapy for advanced pancreatic cancer.
- || Biomarker, Clinical, Journal, Myeloid-derived suppressor cells: Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. (Pubmed Central) - Jun 7, 2020
Skeletal muscle mass may warrant consideration as a predictive factor with which to identify candidates for second-line chemotherapy for advanced pancreatic cancer. Baseline splenomegaly is a prognostic biomarker in patients with mCRC treated with FOLFIRI and bevacizumab, and a surrogate marker of MDSC accumulation.
- || Clinical, Journal: Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). (Pubmed Central) - Jun 5, 2020
Baseline splenomegaly is a prognostic biomarker in patients with mCRC treated with FOLFIRI and bevacizumab, and a surrogate marker of MDSC accumulation. These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery, Metastases: Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer (clinicaltrials.gov) - Jun 5, 2020
P2, N=23, Completed, Sponsor: Fox Chase Cancer Center
These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment. Active, not recruiting --> Completed
- || Clinical, P2 data, Journal: FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. (Pubmed Central) - Jun 5, 2020
Active, not recruiting --> Completed We found no benefit in adding panitumumab or rilotumumab to mFOLFOX6 first-line chemotherapy to treat advanced gastroesophageal adenocarcinoma patients.
- ||| osemitamab (TST001) / Transcenta
Enrollment open, Monotherapy: TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 5, 2020
P1, N=114, Recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
We found no benefit in adding panitumumab or rilotumumab to mFOLFOX6 first-line chemotherapy to treat advanced gastroesophageal adenocarcinoma patients. Not yet recruiting --> Recruiting
- | Enrollment open: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ (clinicaltrials.gov) - Jun 5, 2020
P3, N=340, Recruiting, Sponsor: Universit
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Biomarker, New P2 trial: Neoadjuvant Therapy for Localized Rectal Adenocarcinoma (clinicaltrials.gov) - Jun 4, 2020
P2, N=45, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- || ipatasertib (RG7440) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 4, 2020
P1, N=123, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial completion date: Jan 2020 --> Sep 2020 | Trial primary completion date: Jan 2020 --> Sep 2020
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Jun 4, 2020
P1b, N=430, Recruiting, Sponsor: Amgen
Trial completion date: Jan 2020 --> Sep 2020 | Trial primary completion date: Jan 2020 --> Sep 2020 Trial primary completion date: Jun 2022 --> Feb 2026
- | New P3 trial, Metastases: The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer (clinicaltrials.gov) - Jun 3, 2020
P3, N=627, Recruiting, Sponsor: Fudan University
- | Avastin (bevacizumab) / Roche
Trial suspension, Metastases: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (clinicaltrials.gov) - Jun 1, 2020
P1, N=20, Suspended, Sponsor: Anne Noonan
Trial primary completion date: Jun 2022 --> Feb 2026 Recruiting --> Suspended
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Retrospective data, Journal: The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT: a retrospective study. (Pubmed Central) - May 28, 2020
Recruiting --> Suspended HRR is a new biomarker that can predict DFS and OS in GC patients treated with neoadjuvant FLOT.
- | Biomarker, Journal: From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. (Pubmed Central) - May 28, 2020
HRR is a new biomarker that can predict DFS and OS in GC patients treated with neoadjuvant FLOT. Our pre-planned, prospective analysis suggests that circulating FGF-2 levels' early increase could be used as a marker to identify patients who are more likely to gain benefit from FOLFIRI/bevacizumab first-line therapy.
- || carfilzomib / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - May 27, 2020
P1, N=10, Active, not recruiting, Sponsor: Mehrdad Abedi, MD
Our pre-planned, prospective analysis suggests that circulating FGF-2 levels' early increase could be used as a marker to identify patients who are more likely to gain benefit from FOLFIRI/bevacizumab first-line therapy. Recruiting --> Active, not recruiting | N=21 --> 10 | Trial completion date: Dec 2018 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Nov 2020
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., paclitaxel / Generic mfg.
Clinical, Journal: Definitive re-irradiation of locally recurrent esophageal cancer after trimodality therapy in patients with a poor performance status. (Pubmed Central) - May 27, 2020
In conclusion, definitive re-irradiation of recurrent esophageal cancer in patients with a poor performance status appears to be safe with acceptable acute toxicity and late complications. It also appears to result in durable local control when combined with chemotherapy, albeit with a small number of patients and limited follow-up.
- |||| Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - May 27, 2020
P3, N=823, Active, not recruiting, Sponsor: Takeda
It also appears to result in durable local control when combined with chemotherapy, albeit with a small number of patients and limited follow-up. Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - May 27, 2020
P3, N=757, Active, not recruiting, Sponsor: Takeda
Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021 Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021
- || Opdivo (nivolumab) / BMS, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - May 27, 2020
P1/2, N=40, Recruiting, Sponsor: University of Michigan Rogel Cancer Center
Trial completion date: Jun 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Aug 2021 Suspended --> Recruiting
- | Trial completion, Enrollment change: Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 26, 2020
P1, N=7, Completed, Sponsor: OHSU Knight Cancer Institute
Suspended --> Recruiting Recruiting --> Completed | N=24 --> 7
- ||| leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, Clinical guideline, Journal: Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. (Pubmed Central) - May 23, 2020
The modified combination regimen of 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFIRINOX; oxaliplatin 85 mg/m, leucovorin 400 mg/m, irinotecan 150 mg/m D1, and 5-fluorouracil 2.4 g/m over 46 hours every 14 days for 12 cycles) is now preferred in the absence of concerns for toxicity or tolerance; alternatively, doublet therapy with gemcitabine and capecitabine or monotherapy with gemcitabine alone or fluorouracil plus folinic acid alone can be offered. Additional information can be found at www.asco.org/gastrointestinal-cancer-guidelines .
- || fluorouracil / Generic mfg.
Clinical, Journal: Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. (Pubmed Central) - May 23, 2020
P3
In patients with T4 or perforated colon cancer, treatment with adjuvant HIPEC with oxaliplatin did not improve peritoneal metastasis-free survival at 18 months. Routine use of adjuvant HIPEC is not advocated on the basis of this trial.
- | leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - May 22, 2020
P2, N=162, Not yet recruiting, Sponsor: Emory University
Routine use of adjuvant HIPEC is not advocated on the basis of this trial. Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jan 2022 --> Jun 2022
- | Enrollment change, Mismatch repair, PD(L)-1 Biomarker, IO biomarker: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - May 21, 2020
P3, N=200, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jan 2022 --> Jun 2022 N=347 --> 200
- || Lumakras (sotorasib) / Amgen
Enrollment change, Trial completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - May 21, 2020
P1b, N=430, Recruiting, Sponsor: Amgen
N=347 --> 200 N=250 --> 430 | Trial completion date: Jul 2024 --> Feb 2026
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Review, Journal: The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. (Pubmed Central) - May 21, 2020
Expert treatment recommendations depend on the tumour location, biology, the risk of incomplete (R1) resection, response to treatment, local or systemic recurrence risks, the predicted perioperative morbidity and patients' comorbidities. In summary, any treatment decision requires an interdisciplinary discussion in a comprehensive multidisciplinary setting.
- ||| osemitamab (TST001) / Transcenta
New P1 trial, Monotherapy: TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 21, 2020
P1, N=114, Not yet recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Enrollment closed: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - May 20, 2020
P2, N=136, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
In summary, any treatment decision requires an interdisciplinary discussion in a comprehensive multidisciplinary setting. Suspended --> Active, not recruiting
- | New P2/3 trial: RusGCG-01: FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (clinicaltrials.gov) - May 18, 2020
P2/3, N=538, Recruiting, Sponsor: Blokhin's Russian Cancer Research Center
- ||||| ginisortamab (UCB6114) / UCB
New P1/2 trial, Metastases: ONC001: A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2020
P1/2, N=222, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- | Zaltrap (ziv-aflibercept IV) / Sanofi
New P3 trial, Metastases: TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (clinicaltrials.gov) - May 17, 2020
P3, N=202, Not yet recruiting, Sponsor: GCS IHFB Cognacq-Jay
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study. (Pubmed Central) - May 17, 2020
It could be more frequently associated with a poor ecog ps and a nlr greater than 5 in this group of patients. In patients with mpdac and pcm, either synchronous or metachronous, folfirinox remains an efficient regimen.
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
TRAILing chemoresistance: Oxaliplatin resistance sensitizes colorectal cancer to TRAIL via death receptor localization (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3853;
Additionally, treating whole blood samples from patients with TRAIL-conjugated nanoparticles decreased the number of viable CTCs in circulation 4-fold compared to oxaliplatin monotherapy.These results demonstrate the utility of TRAIL based therapeutics to treat chemoresistant and metastatic CRC. Additionally, this mechanism of apoptosis signal propagation via lipid raft-death receptor complexes can be explored further to probe possible drug targets to augment receptor localization.
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Small slide, big world: Fast detection of altered proteins and RNA levels in clinical samples using Nanostring nCounter® GeoMxTM Digital Spatial Profiler (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2877;
GeoMx DSP platform provides a novel and more precise view of the spatial regulation of micro-world in the tissue, which enable us to explore more about internal regulation within sub-population of the tissue cells.GeoMxTM DSP platform is only for RESEARCH USE ONLY. Not for use in diagnostic procedures.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] OUTCOMES OF CENTRAL NERVOUS SYSTEM PROPHYLAXIS WITH SYSTEMIC HIGH DOSE METHOTREXATE IN DIFFUSE LARGE B-CELL LYMPHOMA IN A DISTRICT GENERAL HOSPITAL () - May 16, 2020 - Abstract #EHA2020EHA_2131;
Conclusion Systemic intravenous HD MTX followed by leucovorin rescue can be adopted for CNS prophylaxis in high risk patients; however it needs to be balanced with the risk of HD MTX toxicity. Studies to better understand optimal dose, quantity and timing of HD MTX are required to achieve optimal CNS prophylaxis.
- || oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, Combination therapy: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (clinicaltrials.gov) - May 15, 2020
P2, N=160, Not yet recruiting, Sponsor: MedImmune LLC
Studies to better understand optimal dose, quantity and timing of HD MTX are required to achieve optimal CNS prophylaxis. Initiation date: Apr 2020 --> Oct 2020
- | New P3 trial: PelvEx II: Induction Chemotherapy for Locally Recurrent Rectal Cancer (clinicaltrials.gov) - May 14, 2020
P3, N=364, Not yet recruiting, Sponsor: Catharina Ziekenhuis Eindhoven
- ||||| PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2 trial, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 14, 2020
P2, N=268, Not yet recruiting, Sponsor: ImmunityBio, Inc.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. (Pubmed Central) - May 14, 2020
Adjuvant chemotherapy after rectal cancer surgery reduces recurrence risks but the benefit is limited and for most patients not clinically relevant. Neoadjuvant therapy can be more effective but results from randomized trials are not yet available.
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
[VIRTUAL] Moderate dose chemotherapy retains efficacy and improves safety in conjunction with high dose ascorbic acid (HDAA) () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_521;
The A.L.A.N. score and its elements defined S subsets.
- leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
[VIRTUAL] Safe moderate dose regimens retain full survival benefits for aged patients with and without resistant gastrointestinal cancers () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_520;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- leucovorin calcium / Generic mfg.
[VIRTUAL] Perioperative FLOT experience: Pathological regression and toxicity () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_485;
Legal entity responsible for the study The authors. Funding Has not received any funding.
- leucovorin calcium / Generic mfg.
[VIRTUAL] Survival outcomes among patients with locally advanced gastric cancer treated within a multidisciplinary gastro-esophageal cancer functional unit () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_466;
Since 2019, the FLOT4-AIO trial showed that perioperative 5FU-leucovorin-oxaliplatin-docetaxel (FLOT) improved median overall survival (mOS) compared to ECF...Legal entity responsible for the study The author. Funding Has not received any funding.
- leucovorin calcium / Generic mfg.
[VIRTUAL] Management of frail patients with metastatic pancreatic ductal adenocarcinoma: A single-institution experience () - May 13, 2020 - Abstract #ESMOGI2020ESMO_GI_461;
Legal entity responsible for the study The author. Funding Has not received any funding.